Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 81. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 20193107
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series992
Challenges in the diagnosis of Parkinson's disease672
APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches485
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group482
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation448
Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria424
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis374
Traumatic brain injury: progress and challenges in prevention, clinical care, and research344
Myelin-oligodendrocyte glycoprotein antibody-associated disease319
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias298
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study294
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial281
New insights into atypical Alzheimer's disease in the era of biomarkers277
Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study269
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial256
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI–neuropathology diagnostic accuracy study244
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study237
Neuroimaging standards for research into small vessel disease—advances since 2013222
The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data209
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study206
Multiple sclerosis progression: time for a new mechanism-driven framework203
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials192
Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis184
The neuropsychiatry of Parkinson's disease: advances and challenges182
Progress towards therapies for disease modification in Parkinson's disease180
Functional neurological disorder: new subtypes and shared mechanisms176
Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis175
Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation173
Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease169
Moyamoya disease: diagnosis and interventions148
Monogenic variants in dystonia: an exome-wide sequencing study147
Intracranial pressure monitoring in patients with acute brain injury in the intensive care unit (SYNAPSE-ICU): an international, prospective observational cohort study145
Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts142
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities141
Neuromodulation in epilepsy: state-of-the-art approved therapies139
PET imaging of neuroinflammation in neurological disorders139
Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder138
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial137
Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial134
Post-viral effects of COVID-19 in the olfactory system and their implications133
Intracranial atherosclerotic stenosis: risk factors, diagnosis, and treatment128
Alzheimer's disease associated with Down syndrome: a genetic form of dementia127
Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study127
Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies125
Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis124
A biological classification of Huntington's disease: the Integrated Staging System124
Diagnosis and classification of optic neuritis118
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials117
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial117
Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances117
Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial115
Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials115
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial113
Forecasting seizure risk in adults with focal epilepsy: a development and validation study109
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, 106
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021105
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study105
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial105
Mitochondrial disease in adults: recent advances and future promise105
Cholinergic system changes in Parkinson's disease: emerging therapeutic approaches103
SARS-CoV-2 and the risk of Parkinson's disease: facts and fantasy102
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research101
New therapies for neuromyelitis optica spectrum disorder101
Epilepsy in China: major progress in the past two decades100
Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments99
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders98
Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study96
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria95
Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study95
Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations92
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial90
Thrombolysis for acute ischaemic stroke: current status and future perspectives88
Amantadine in the treatment of Parkinson's disease and other movement disorders88
Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission87
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial86
Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial84
Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment84
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)82
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study81
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial81
Ageing and multiple sclerosis81
0.043622970581055